FrancophonIA/ELRC3.0 huggingface dataset:
English: Mean peak plasma levels were approximately 1 ng/ml and 2 ng/ml for the 0.5 and 1.0 mg/ml treatments respectively.
Estonian: Keskmine maksimaalne plasma-kontsentratsioon oli ligikaudu 1 ng/ml ja 2 ng/ml vastavalt 0,5 ja 1,0 mg/ml ravimi manustamisele.
English: In vitro examinations of emedastine's affinity for histamine receptors (H1, H2, and H3) demonstrate 10,000-fold selectivity for the H1 receptor, Ki's = 1.3 nM, 49,064 nM and 12, 430 nM, respectively.
Estonian: In vitro uuringutes emedastiini afiinsuse suhtes histamiini retseptoritele (H1, H2 ja H3) ilmnes 10 000 kordne selektiivsus H1 suhtes, vastavalt Ki = 1,3 nM, 49,064 nM ja 12,430 nM. In vivo paikne manustamine silma kutsub esile kontsentratsioonist sõltuva konjunktiivi veresoonte histamiinist tingitud permeaabelsuse suurenemise pärssimise.
English: What EMADINE contains - The active substance is emedastine 0.5 mg/ml as difumarate.
Estonian: Mida EMADINE sisaldab - Toimeaine on emedastiin 0,5 mg/ml difumaraadina.
English: Emedastine was found to increase the QT interval in dogs; the NOEL corresponds to levels 23-fold higher than those found in patients (7 ng/ml as compared with 0.3 ng/ml, i.e., the limit of detection for emedastine).
Estonian: NOEL on vastavalt 23 korda kõrgem kui patsientidel (7 ng/ml võrrelduna 0,3 ng/ml, e emedastiini avastamise madalaim tase).
English: Talk to your doctor or pharmacist before using EMADINE.
Estonian: Enne EMADINE'i kasutamist pidage nõu oma arsti või apteekriga.
English: Uncommon corneal infiltrates, corneal staining, blurred vision, eye irritation, dry eye, foreign body sensation in eyes, lacrimation increased, asthenopia, ocular hyperaemia
Estonian: Sarvkesta infiltraadid, sarvkesta pigmenteerumine, hägune nägemine, silma ärritus, kuivsilmsus, võõrkeha tunne silmas, suurenenud pisaravool, astenoopia, silma hüpereemia
English: After cap is removed, if tamper evident snap collar is loose, remove before using product.
Estonian: Kui juhuslikku avamist välistav äratõmmatav kinnitusrõngas on pärast korgi eemaldamist lahti tulnud, eemaldage see enne ravimi kasutamist.
English: Contains: trometamol, sodium chloride, hypromellose, hydrochloric acid, sodium hydroxide and purified water.
Estonian: Sisaldab: trometamool, naatriumkloriid, hüpromelloos, soolhape, naatriumhüdroksiid ja puhastatud vesi.
English: EMADINE Ocular use
Estonian: EMADINE Okulaarne
English: Emedastine 0.5 mg/ml as difumarate
Estonian: Emedastiin 0,5 mg/ml difumaraadina
English: In case of accidental ingestion of the content of a bottle of EMADINE, sedative effects may occur and the potential of emedastine to increase the QT interval should be borne in mind and appropriate monitoring and management should be implemented.
Estonian: Terve pudeli EMADINE'i juhuslikul suukaudsel manustamisel tuleb meeles pidada, et ravim võib toimida sedatiivselt ja potentsiaalselt pikendada QT-intervalli.
English: Do not use a double dose to make up for the one missed.
Estonian: Ärge võtke kahekordset annust, kui annus jäi eelmisel korral võtmata.
English: BOX OF 1 BOTTLE, 5 ml & 10 ml
Estonian: PUDELI SILT, 5 ml ja 10 ml
English: Elderly Population
Estonian: Eakad patsiendid
English: • Throw away the container and any leftover solution at once.
Estonian: - Visake konteiner ja sellesse jäänud ravim kohe ära.
English: The drop will go in here.
Estonian: Ravimi tilk peab minema sellesse taskusse.
English: • General side effects: headache, difficulty sleeping, sinus headache, bad taste, rash
Estonian: • Üldised kõrvaltoimed: peavalu, magamisraskused, nina kõrvalurgetest tingitud peavalu,
English: Common eye pain, eye pruritus, conjunctival hyperaemia
Estonian: Silmavalu, silma kihelus, konjunktiivi hüpereemia
English: What EMADINE looks like and the contents of the pack EMADINE is a liquid (a solution) supplied in a pack containing a 5 ml or 10 ml plastic (DROP-TAINER) bottle with a screw cap. Not all pack sizes may be marketed.
Estonian: Kuidas EMADINE välja näeb ja pakendi sisu EMADINE on vedelik (lahus), mida toodetakse üksikannusena plastikust keeratava korgiga konteineris suurusega 5 ml või 10 ml.
English: • Don't touch your eye or eyelid, surrounding areas or other surfaces with the dropper.
Estonian: - Ärge puudutage tilguti otsikuga silma, silmalaugu ega teisi ümbritsevaid pindu.
English: EMADINE 0.5 mg/ml eye drops, solution, single-dose container.
Estonian: EMADINE 0,5 mg/ml silmatilgad, lahus, üksikannusega konteiner.
English: Tiny amounts of hydrochloric acid or sodium hydroxide are sometimes added to keep acidity levels (pH levels) normal
Estonian: Väikestes kogustes võib olla lisatud soolhapet või naatriumhüdroksiidi, et tagada sobiv happelisus (pH tasakaalustamiseks).
English: In case of corneal infiltrates, the product should be discontinued and appropriate management should be implemented.
Estonian: Sellisel juhul tuleb ravimi kasutamine lõpetada ja määrata vastav ravi.
English: • Don't touch your eye or eyelid, surrounding areas or other surfaces with the container tip.
Estonian: - Ärge puudutage konteineri otsaga silma, silmalaugu ega teisi ümbritsevaid pindu.
English: Discard any unused contents of a single use container immediately after use.
Estonian: Visake üksikannusega konteiner koos kasutamata jäänud ravimiga ära kohe pärast manustamist.
English: - The other ingredients are benzalkonium chloride, trometamol; sodium chloride; hypromellose;
Estonian: - Teised koostisosad on bensalkooniumkloriid, trometamool, naatriumkloriid, hüpromelloos,
English: Emedastine has been identified in the milk of rats following oral administration.
Estonian: Pärast emedastiini suukaudset manustamist rottidele leiti seda nende piimast.
English: There was no evidence of impaired fertility or decreased reproductive capacity in rats administered oral dosages of Emedastine difumarate of up to 30 mg/kg/day.
Estonian: Pärast emedastiindifumaraadi suukaudset manustamist rottidele annustes kuni 30 mg/kg ööpäevas ei leitud tõendeid fertiilsuse kahjustuse või reproduktiivsete võimete vähenemise kohta.
English: To prevent contamination of the dropper tip and solution, care should be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.
Estonian: Tilguti otsikuga ei tohi puudutada silmalauge, piirnevaid alasid või teisi pindu, et vältida tilguti otsiku ja lahuse saastumist.
English: • Effects in the eye: corneal disorder, abnormal eye sensation, increased tear production, tired eyes, eye irritation, blurred vision, corneal staining, dry eye.
Estonian: • Kõrvaltoimed silmas: sarvkesta haigus, võõrkehatunne silmas, suurenenud pisaraeritus, väsinud silmad, silma ärritus, hägune nägemine, sarvkesta pigmenteerumine, kuivsilmsus.
English: Emedastine difumarate was not found to be carcinogenic in studies in mice and rats.
Estonian: Uuringutes rottide ja hiirtega leiti, et emedastiin difumaraat ei ole kartsinogeenne.
English: Emedastine difumarate was not genotoxic in a standard battery of in vitro and in vivo genotoxicity assays.
Estonian: Standardsetes in vitro ja in vivo genotoksilisuse uuringuis leiti, et emedastiin difumaraat ei oma genotoksilist toimet.
English: Five single-dose containers are then presented in a foil pouch.
Estonian: Üksikannused on pakendatud viie kaupa fooliumümbrisesse.
English: MARKETING AUTHORISATION NUMBERS
Estonian: MÜÜGILOA NUMBER(NUMBRID)
English: - The other ingredients are trometamol; sodium chloride; hypromellose; purified water.
Estonian: - Teised koostisosad on trometamool, naatriumkloriid, hüpromelloos, puhastatud vesi.
English: 1 ml of solution contains emedastine 0.5 mg (as difumarate).
Estonian: 1 ml lahust sisaldab emedastiini (emedastinum) 0,5 mg difumaraadina.
English: Scleral mononuclear cell infiltrates were present in 1/4 males and 1/4 females treated with 0.5 mg/ml and in 2/4 males and 1/4 females treated with 1.0 mg/ml.
Estonian: Skleraalsed mononukleaarsete rakkude infiltraadid esinesid 1/4 isastel ja 1/4 emastel, kellel manustati ravimit 0,5 mg/ml ning 2/4 isastel ja 1/4 emastel, kellele manustati ravimit 1,0 mg/ml.
English: • Hold the long flat end of the container between your thumb and forefinger and open it by twisting off the other end (picture 2).
Estonian: Avage konteiner teist otsa ära keerates (joonis 2).
English: EMADINE 0.5 mg/ml, eye drops, solution
Estonian: EMADINE 0,5 mg/ml, silmatilgad, lahus
English: • After cap is removed, if tamper evident snap collar is loose, remove before using product.
Estonian: - Kui juhuslikku avamist välistav äratõmmatav kinnitusrõngas on pärast korgi eemaldamist lahti tulnud, eemaldage see enne ravimi kasutamist.
English: Belgium.
Estonian: Belgia
English: The recommended dose < see side 1
Estonian: Soovitatav annus <vt I pool
English: • Bring the bottle tip close to the eye. Use the mirror if it helps.
Estonian: - Viige pudeli otsik silmale lähemale.
English: Corneal limbal mononuclear cell infiltrates were noted in 1/4 male monkeys treated with 0.5 mg/ml and in 4/4 males and 1/4 females treated with1.0 mg/ml.
Estonian: Sarvkesta limbaalseid mononukleaarsete rakkude infiltraate täheldati 1/4 isastel ahvidel, kellele manustati ravimit 0,5 mg/ml ja 4/4 isastel ja 1/4 emastel, kellele manustati ravimit 1,0 mg/ml.
English: 1 ml of solution contains emedastine 0.5 mg (as difumarate)
Estonian: 1 ml lahust sisaldab emedastiini (emedastinum) 0,5 mg difumaraadina
English: EMADINE 0.5 mg/ml eye drops, solution, single-dose container emedastine
Estonian: EMADINE 0,5 mg/ml silmatilgad, lahus, üksikannusega konteiner
English: Novartis Farma - Produtos Farmacêuticos, S.A.
Estonian: Novartis Farma S.p.A.
English: In a study involving ten normal volunteers dosed bilaterally twice daily for 15 days with EMADINE 0.5 mg/ml eye drops solution, plasma concentrations of the parent compound were generally below the quantitation limit of the assay (0.3 ng/ml).
Estonian: Uuringus 10 terve vabatahtlikuga tilgutati EMADINE 0,5 mg/ml silmatilku kaks korda päevas mõlemasse silma 15 päeva jooksul.
English: No serious ophthalmic or systemic adverse drug reactions were reported in the clinical trials.
Estonian: Mingeid tõsiseid silmadega seotud või süsteemseid kõrvaltoimeid ei esinenud.
English: • Bring the container tip close to the eye. Use the mirror if it helps.
Estonian: - Viige konteineri ots silmale lähemale.
English: What EMADINE looks like and the contents of the pack EMADINE is a liquid (a solution) supplied in single-dose plastic containers which contain 0.35 ml.
Estonian: EMADINE on vedelik (lahus), mida toodetakse üksikannusena plastikust keeratava korgiga konteineris suurusega 0,35 ml.
English: Tabulated list of adverse reactions
Estonian: Kõrvaltoimete loetelu tabelis
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Estonian: Kuidas EMADINE välja näeb ja pakendi sisu
English: Nervous system disorders Uncommon headache, sinus headache, dysgeusia
Estonian: Peavalu, nina kõrvalurgetest tingitud peavalu, düsgeusia
English: Hepatic and Renal impairment Use
Estonian: Neeru- ja maksahaiged
English: Discard any unused containers one week after first opening pouch.
Estonian: Visake ära kasutamata jäänud konteinerid ümbrisest, mis on olnud avatud üle ühe nädala.
English: Frequency
Estonian: Imendumine
English: You must throw away the container as soon as you have used it. Once the foil wrapper has been opened any unused containers must be thrown away one week after you first opened it.
Estonian: Kõik kasutamata jäänud konteinerid tuleb ära visata fooliumümbrisest, mis on olnud avatud rohkem kui üks nädal.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Procysbi on 06.09.2013.
Estonian: Euroopa Komisjon andis Procysbi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil,06.09.2013.
English: The amount of cystine in the organs is therefore reduced, and this limits the damage to these organs.
Estonian: Tsüstiini kogus elundites väheneb ning see piirab nende elundite kahjustumist.
English: What measures are being taken to ensure the safe and effective use of Procysbi?
Estonian: Mis meetmed võetakse, et tagada Procysbi ohutu ja efektiivne kasutamine?
English: Procysbi is available as gastroresistant capsules (25 and 75 mg).
Estonian: Procysbit turustatakse gastroresistentsete kapslitena (25 ja 75 mg).
English: A risk management plan has been developed to ensure that Procysbi is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Procysbi võimalikult ohutu kasutamine.
English: Procysbi mercaptamine
Estonian: Procysbi merkaptamiin
English: In a main study involving 43 patients with nephropathic cystinosis, there was no meaningful difference between the average levels of cystine in white blood cells during a 3-week treatment with the two medicines.
Estonian: Põhiuuringus, kuhu oli kaasatud 43 nefropaatilise tsüstinoosiga patsienti, ei täheldatud kahe ravimiga kestnud kolmenädalase ravi vältel vere valgeliblede tsüstiini keskmise sisalduses olulist erinevust.
English: It must also not be used in women who are breastfeeding.
Estonian: Samuti ei tohi seda kasutada imetamise ajal.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Procysbi's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Procysbi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Levels were 0.51 nmol/mg with Procysbi, compared with 0.44 nmol/mg with Cystagon.
Estonian: Procysbi korral oli tsüstiinisisaldus 0,51 nmol/mg ja Cystagoni korral 0,44 nmol/mg.
English: The recommended daily dose is calculated according to body surface area, as 1.30 g per m2 divided into 2 doses given every 12 hours.
Estonian: Kehapindala alusel arvutatud soovitatav ööpäevane annus 1,30 g ruutmeetri kohta jagatakse kaheks annuseks, mis manustatakse iga 12 tunni järel.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Procysbi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Procysbi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The most common side effects with Procysbi (which may affect more than 1 in 10 people) are loss of appetite, vomiting, nausea (feeling sick), diarrhoea, lethargy (lack of energy) and pyrexia (fever).
Estonian: Procysbi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on isutus, oksendamine, iiveldus, kõhulahtisus, letargia (energiapuudus) ja püreksia (palavik).
English: What is Procysbi and what is it used for?
Estonian: Mis on Procysbi ja milleks seda kasutatakse
English: Because the number of patients with cystinosis is low, the disease is considered ‘rare', and Procysbi was designated an ‘orphan medicine' (a medicine used in rare diseases) on 20 September 2010.
Estonian: Et tsüstinoosiga patsientide arv on väike ja see haigus esineb harva, nimetati Procysbi 20. septembril 2010 harvikravimiks.
English: Other information about Procysbi
Estonian: Muu teave Procysbi kohta
English: Procysbi must not be used in people who are hypersensitive (allergic) to any form of mercaptamine or any of the other ingredients, or to penicillamine.
Estonian: Procysbit ei tohi kasutada patsientidel, kes on merkaptamiini mis tahes ravimvormi, mis tahes teiste koostisosade või penitsillamiini suhtes ülitundlikud (allergilised).
English: Why is Procysbi approved?
Estonian: Miks Procysbi heaks kiideti?
English: The full EPAR for Procysbi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Procysbi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In addition, the company that markets Procysbi will provide educational material to all doctors expected to prescribe the medicine, containing important safety information including the risk that the medicine may be harmful to the unborn child.
Estonian: Lisaks varustab Procysbit turustav ettevõtte kõik ravimit eeldatavalt välja kirjutavad arstid teabematerjaliga, mis sisaldab olulist ohtusteavet ja käsitleb muu hulgas ravimi võimalikku kahjulikku toimet sündimata lapsele.
English: Cystinosis is an inherited disease in which excess amounts of cystine, an amino acid naturally found in the body, build up within cells, especially in the kidneys and the eyes, damaging them.
Estonian: Tsüstinoos on pärilik haigus, mille korral organismis leiduv aminohape tsüstiin koguneb ülemääraselt rakkudesse (eeskätt neerudesse ja silmadesse) ning kahjustab neid.
English: Procysbi is a medicine that contains the active substance mercaptamine (also known as cysteamine).
Estonian: Procysbi on ravim, mis sisaldab toimeainena merkaptamiini (tuntud ka tsüsteamiinina).
English: This means that it is similar to a ‘reference medicine' containing the same active substance, but Procysbi is available in a formulation that allows for a delayed release of the active substance in the body.
Estonian: See tähendab, et Procysbi on sama toimeainet sisaldava võrdlusravimiga sarnane, kuid Procysbit turustatakse ravimvormis, mis võimaldab toimeainet viivitatult organismi vabastada.
English: What are the risks associated with Procysbi?
Estonian: Mis riskid Procysbiga kaasnevad?
English: Regarding its safety, the CHMP considered that the safety profile of mercaptamine is well established and the safety of Procysbi is expected to be similar to that of the reference medicine.
Estonian: Ohutuse kohta arvas oli inimravimite komitee, et merkaptamiini ohutusprofiil on hästi tõendatud ja Procysbi ohutus on oodatavalt sarnane võrdlusravimiga.
English: This is a summary of the European public assessment report (EPAR) for Procysbi.
Estonian: See on ravimi Procysbi Euroopa avaliku hindamisaruande kokkuvõte.
English: The Committee also considered that the gastroresistant formulation, due to its less frequent administration, is expected to increase compliance with treatment and the quality of life of patients with cystinosis.
Estonian: Samuti leidis komitee, et tänu harvemale manustamisintervallile suurendab gastroresistentne ravimvorm eeldatavalt ravivastust ning parandab tsüstinoosiga patsientide elukvaliteeti.
English: It is not intended to provide practical advice on how to use Procysbi.
Estonian: Hindamisaruandes ei anta Procysbi kasutamise praktilisi nõuandeid.
English: The reference medicine for Procysbi is Cystagon.
Estonian: Procysbi võrdlusravim on Cystagon.
English: Procysbi can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of cystinosis.
Estonian: Procysbi on retseptiravim ning ravi tohib alustada tsüstinoosi ravimise kogemustega arsti järelevalve all.
English: Gastroresistant means that the capsules' contents pass through the stomach without being broken down until they reach the intestine.
Estonian: Gastroresistentsus tähendab, et kapsli sisu läbib mao ega lagune enne, kui kapsel jõuab soolestikku.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Procysbi, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Procysbi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavate ettevaatusmeetmete teave.
English: For practical information about using Procysbi, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Procysbi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Procysbi is a ‘hybrid medicine'.
Estonian: Procysbi on hübriidravim.
English: It is used in patients with nephropathic (kidney) cystinosis.
Estonian: Seda kasutatakse nefropaatilise (neerude) tsüstinoosiga patsientidel.
English: The active substance in Procysbi, mercaptamine, reacts with cystine to form another amino acid, called cysteine, and a compound called a cysteine-cysteamine salt.
Estonian: Procysbi toimeaine merkaptamiin reageerib tsüstiiniga ning moodustab teise aminohappe, tsüsteiini, ja ühendi, mis on tsüsteiini-tsüsteamiini sool.
English: For more information about treatment with Procysbi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Procysbiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For the full list of all side effects reported with Procysbi, see the package leaflet.
Estonian: Procysbi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Cystine levels in white blood cells (which are measured as nmol hemicystine per mg white blood cell protein), or alternatively mercaptamine concentration in the blood, should be monitored and used to adjust the dose, which should never exceed 1.95 g per m2 per day.
Estonian: (mõõteühik on nmol hemitsüstiini leukotsüüdi valgu mg kohta) või merkaptamiini kontsentratsiooni veres ning ööpäevane annus ei tohi kunagi olla suurem kui 1,95 g kehapindala ruutmeetri kohta.
English: How does Procysbi work?
Estonian: Kuidas Procysbi toimib?
English: Procysbi given every 12 hours has been shown to be at least as effective as Cystagon given every 6 hours at maintaining the amount of cystine in white blood cells at acceptable levels (less than 1 nmol hemicystine per mg of white blood cell protein).
Estonian: On tõendatud, et iga 12 tunni järel manustatav Procysbi on vere leukotsüütide tsüstiinisisalduse aktsepteeritaval tasemel (vähem kui 1 nmol hemitsüstiini leukotsüüdi valgu mg kohta) hoidmisel vähemalt sama efektiivne kui iga 6 tunni järel manustatav Cystagon.
English: How is Procysbi used?
Estonian: Kuidas Procysbit kasutatakse?
English: The CHMP noted that Procysbi was shown to be at least as effective as Cystagon at maintaining the amount of cystine in white blood cells at acceptable levels.
Estonian: Inimravimite komitee täheldas, et Procysbi hoiab vere leukotsüütide tsüstiinisisalduse aktsepteeritaval tasemel vähemalt sama efektiivselt kui Cystagon.
English: What benefits of Procysbi have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Procysbi kasulikkus?
English: Hepatitis that may be serious.
Estonian: Hepatiit, mis võib olla tõsine.
English: How long should I take alli for?
Estonian: Kui kaua peab alli't võtma?
English: However, any possible risk should be avoided (see section 6.6).
Estonian: Kuid mistahes võimalikke riske tuleks vältida (vt lõik 6.6).
English: Do not swallow them.
Estonian: Ärge neelake neid alla.
English: FURTHER HELPFUL INFORMATION
Estonian: TÄIENDAV KASULIK TEAVE
English: The more active you are, the higher your calorie target.
Estonian: Mida aktiivsem te olete, seda suurem on teie kalorite eesmärkväärtus.
English: Do not use
Estonian: Ärge kasutage
English: 24018, 1700 Λευκωσία
Estonian: 24018, 1700 Λευκωσία Tηλ.
English: What you need to know before you take alli
Estonian: Mida on vaja teada enne alli võtmist
English: All comparisons against placebo were statistically significant.
Estonian: Kõik võrdlused platseeboga olid statistiliselt olulised.
English: Other medicines and alli alli may affect some medicines you have to take.
Estonian: Muud ravimid ja alli alli võib mõjutada mõnede teiste ravimite toimet, mida te peate võtma.
English: - if you are under 18 years old.
Estonian: - kui olete alla 18-aastane.
English: If you are unsure which level you are, choose Low activity.
Estonian: Kui te ei ole kindel, millise kehalise aktiivsuse taseme te peaksite valima, siis valige vähene kehaline aktiivsus.
English: What alli contains
Estonian: Mida alli sisaldab
English: Therefore orlistat treatment should only be initiated after careful consideration of the possible impact in these patients.
Estonian: Seetõttu tohib alustada ravi orlistaadiga ainult pärast hoolikat kaalutlust võimalikust mõjust nendele patsientidele.